NO20055179L - Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid - Google Patents

Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid

Info

Publication number
NO20055179L
NO20055179L NO20055179A NO20055179A NO20055179L NO 20055179 L NO20055179 L NO 20055179L NO 20055179 A NO20055179 A NO 20055179A NO 20055179 A NO20055179 A NO 20055179A NO 20055179 L NO20055179 L NO 20055179L
Authority
NO
Norway
Prior art keywords
retionide
macrolide
immunosuppressant
synergistic combinations
cell modulator
Prior art date
Application number
NO20055179A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055179D0 (no
Inventor
Maximillan Grassberger
Stefan Hirsch
Anton Stuetz
Josef Gottried Meingassner
Nabila Sekkat
Carle Paul
Karl Friedrich Mayer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20055179D0 publication Critical patent/NO20055179D0/no
Publication of NO20055179L publication Critical patent/NO20055179L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055179A 2003-04-04 2005-11-03 Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid NO20055179L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307864.9A GB0307864D0 (en) 2003-04-04 2003-04-04 Pharmaceutical composition
PCT/EP2004/003511 WO2004087118A2 (en) 2003-04-04 2004-04-02 Synergistic combinations of macrolide t-cell modulator or inmunosuppressant and a retinoid

Publications (2)

Publication Number Publication Date
NO20055179D0 NO20055179D0 (no) 2005-11-03
NO20055179L true NO20055179L (no) 2006-01-04

Family

ID=9956227

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055179A NO20055179L (no) 2003-04-04 2005-11-03 Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid

Country Status (13)

Country Link
US (1) US20060100187A1 (de)
EP (1) EP1638543A2 (de)
JP (1) JP2006522057A (de)
CN (1) CN100475199C (de)
AU (1) AU2004226819B2 (de)
BR (1) BRPI0408959A (de)
CA (1) CA2518245A1 (de)
GB (1) GB0307864D0 (de)
IS (1) IS8112A (de)
MX (1) MXPA05010701A (de)
NO (1) NO20055179L (de)
RS (1) RS20050660A (de)
WO (1) WO2004087118A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234250A1 (en) * 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
EP2432453A2 (de) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Topische retinoid-lösungen
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
PL368556A1 (en) * 2001-02-01 2005-04-04 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva
US20030021816A1 (en) * 2001-06-06 2003-01-30 Sewon Kang Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
US7887842B2 (en) * 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
GB0307862D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
WO2004087118A3 (en) 2005-04-07
RS20050660A (sr) 2007-11-15
CN100475199C (zh) 2009-04-08
AU2004226819A1 (en) 2004-10-14
BRPI0408959A (pt) 2006-04-04
CA2518245A1 (en) 2004-10-14
AU2004226819B2 (en) 2008-02-28
CN1764444A (zh) 2006-04-26
WO2004087118A2 (en) 2004-10-14
IS8112A (is) 2005-11-01
GB0307864D0 (en) 2003-05-14
JP2006522057A (ja) 2006-09-28
MXPA05010701A (es) 2005-12-12
EP1638543A2 (de) 2006-03-29
NO20055179D0 (no) 2005-11-03
US20060100187A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CY1106628T1 (el) Τοπικες φαρμακευτικες συνθεσεις περιλαμβανουσες προανθοκυανιδινες, γλυκυρροχητινικο οξυ και τελμεστεϊνη για τη θεραπεια των δερματιτιδων
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
TW200731978A (en) User-adjustable treatment methods, systems and compositions for treating acne
WO2007096601A3 (en) Antimicrobial formulations comprising a quinone and a copper salt
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
WO2007092312A3 (en) Topical skin treating compositions
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
ECSP11010762A (es) Composición tópica para el tratamiento de queratosis actínica
WO2008079363A3 (en) Substituted tetracycline compounds for treatment of inflammatory skin disorders
ATE461928T1 (de) Antibakterielle wirkstoffe
BR112022019794A2 (pt) Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)
WO2006083979A3 (en) Local treatment of neurofibromas
EP4297724A4 (de) Mikronadeln und verfahren zur behandlung der haut
WO2005115546A3 (en) Dimethyl sulfone for the treatment of rosacea
WO2006120681A3 (en) Compositions and methods for skin care
NO20055136L (no) Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer
WO2007065289A3 (en) 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
WO2003092621A3 (en) Composition and method for dermatological treatment
WO2006081182A3 (en) Antibacterial agents
NO20055179L (no) Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid
ATE484509T1 (de) Antibakterielle mittel
WO2006081178A3 (en) Antibacterial agents
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
EP3381437A3 (de) Topische zusammensetzungen mit retinoiden und polymeren reinigungsmitteln mit geringer reizung
MX2007011486A (es) Formulaciones topicas de antibioticos de acido borinico y sus metodos de uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application